TABLE 6.
Percent of Pathogens Reported From Central Line–Associated Bloodstream Infections (CLABSIs) That Tested Resistant to Selected Antimicrobial Agents, by Period, 2011–2014
| Pathogen, antimicrobial | 2011 | 2012 | 2013 | 2014 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of isolates reported | % of isolates testeda | % Resistance | No. of isolates reported | % of isolates testeda | % Resistance | No. of isolates reported | % of isolates testeda | % Resistance | No. of isolates reported | % of isolates testeda | % Resistance | |
| Staphylococcus aureus | 3,022 | 3,087 | 3,358 | 3,239 | ||||||||
| OX/METH/CEFOX | 93.3 | 52.6 | 92.6 | 51.1 | 91.0 | 52.3 | 90.3 | 50.7 | ||||
| Enterococcus spp. | ||||||||||||
| E. faecium | 1,550 | 1,532 | 1,756 | 1,729 | ||||||||
| VAN | 95.7 | 83.8 | 96.2 | 83.3 | 94.3 | 83.0 | 94.8 | 82.2 | ||||
| E. faecalis | 1,984 | 2,080 | 2,107 | 1,947 | ||||||||
| VAN | 93.5 | 9.9 | 93.2 | 10.1 | 93.5 | 9.3 | 93.9 | 9.8 | ||||
| Klebsiella (pneumoniae/oxytoca) | 1,851 | 1,936 | 2,075 | 2,200 | ||||||||
| ESC4 | 85.6 | 28.3 | 84.9 | 28.1 | 85.8 | 28.5 | 85.1 | 24.1 | ||||
| Carbapenems | 74.8 | 11.3 | 75.8 | 13.0 | 74.8 | 13.1 | 73.3 | 10.9 | ||||
| MDR1 | 90.2 | 20.9 | 91.6 | 20.3 | 92.9 | 20.3 | 92.6 | 17.2 | ||||
| Escherichia coli | 956 | 1,167 | 1,475 | 1,595 | ||||||||
| ESC4 | 85.1 | 19.7 | 83.5 | 22.2 | 84.9 | 24.4 | 84.6 | 22.2 | ||||
| FQ3 | 91.6 | 41.1 | 90.8 | 42.5 | 89.4 | 47.8 | 90.1 | 49.3 | ||||
| Carbapenems | 74.4 | 1.3 | 73.2 | 1.3 | 71.2 | 2.1 | 70.9 | 1.9 | ||||
| MDR1 | 90.2 | 11.1 | 90.7 | 13.8 | 92.1 | 14.9 | 90.9 | 14.1 | ||||
| Enterobacter spp. | 1,000 | 1,029 | 1,106 | 1,069 | ||||||||
| ESC4 | 93.5 | 37.3 | 91.6 | 38.2 | 91.9 | 37.7 | 89.8 | 36.1 | ||||
| Carbapenems | 76.7 | 3.0 | 74.2 | 5.2 | 72.8 | 6.2 | 70.7 | 6.6 | ||||
| MDR1 | 93.9 | 8.1 | 93.1 | 10.0 | 93.2 | 10.4 | 92.2 | 9.5 | ||||
| Pseudomonas aeruginosa | 888 | 877 | 1,100 | 1,016 | ||||||||
| AMINOS | 92.5 | 22.0 | 96.9 | 17.5 | 94.5 | 20.5 | 94.0 | 17.2 | ||||
| ESC2 | 92.1 | 27.1 | 95.2 | 23.2 | 92.5 | 26.6 | 92.7 | 24.2 | ||||
| FQ2 | 93.8 | 33.1 | 92.9 | 28.3 | 90.5 | 31.4 | 92.2 | 30.2 | ||||
| Carbapenems | 83.8 | 28.4 | 84.3 | 23.7 | 83.1 | 25.4 | 80.9 | 25.8 | ||||
| PIP/PIPTAZ | 81.0 | 19.9 | 82.3 | 17.9 | 84.6 | 19.0 | 87.2 | 18.4 | ||||
| MDR2 | 95.0 | 21.7 | 96.9 | 16.7 | 93.9 | 19.0 | 94.4 | 17.9 | ||||
| Acinetobacter spp. | 544 | 572 | 538 | 495 | ||||||||
| Carbapenems | 83.3 | 57.2 | 82.7 | 49.5 | 79.7 | 53.1 | 76.4 | 46.6 | ||||
| MDR3 | 96.3 | 60.9 | 95.3 | 51.6 | 95.2 | 52.7 | 92.9 | 43.7 | ||||
NOTE. OX/METH/CEFOX, oxacillin/methicillin/cefoxitin; VAN, vancomycin; ESC4, extended-spectrum cephalosporin (cefepime, cefotaxime, ceftazidime, ceftriaxone); Carbapenems (imipenem, meropenem, doripenem); MDR1, multidrug-resistance (must test either intermediate [I] or resistant [R] to at least 1 drug in 3 of the 5 following classes [ESC4, FQ3, AMINO, carbapenems, & PIP/PIPTAZ]); FQ3, fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin); AMINOS, aminoglycosides (amikacin, gentamicin, tobramycin); ESC2, extended-spectrum cephalosporin (cefepime, ceftazidime); FQ2, fluoroquinolones (ciprofloxacin, levofloxacin); PIP, piperacillin; PIPTAZ, piperacillin/tazobactam; MDR2, multidrug-resistance (must test either I or R to at least 1 drug in 3 of the 5 following classes [ESC2, FQ2, AMINOS, carbapenems, & PIP/PIPTAZ]); MDR3, multidrug-resistance (must test either I or R to at least 1 drug in 3 of the 6 following classes [ESC4, FQ2, AMINOS, carbapenems, PIP/PIPTAZ & ampicillin/sulbactam]).
If the percent of isolates tested is less than 70%, caution should be used when interpreting the percent resistance.